Intranasal vaccine against COVID-19 based on a recombinant variant of the Sendai virus (Paramyxoviridae: <i>Respirovirus</i>) strain Moscow

Intranasal vaccine against COVID-19 based on a recombinant variant of the Sendai virus (Paramyxoviridae: <i>Respirovirus</i>) strain Moscow

Introduction. Intranasal vaccination using live vector vaccines based on non-pathogenic or slightly pathogenic viruses is the one of the most convenient, safe and effective ways to prevent respiratory infections, including COVID-19. Sendai virus is the best suited for this purpose, since it is respi...

Full description

Bibliographic Details
Main Authors: Gleb A. Kudrov, Sergei S. Zainutdinov, Antonina A. Grazhdantseva, Andrey V. Shipovalov, Galina F. Sivolobova, Anastasiya V. Semenova, Iuliia A. Merkuleva, Dmitry N. Shcherbakov, Oleg S. Taranov, Anna V. Zaykovskaya, Irina S. Shulgina, Oleg V. Pyankov, Galina V. Kochneva
Format: Article
Language:English
Published: Central Research Institute for Epidemiology 2023-07-01
Series:Вопросы вирусологии
Subjects:
sendai virus
recombinant variant of the virus
sars-cov-2
rbd
immunogenicity
protectiveness
Online Access:https://virusjour.crie.ru/jour/article/viewFile/7167/778

Similar Items

Similar Items